130 results on '"Weiying Gu"'
Search Results
2. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
- Author
-
Linyan Cheng, Lujun Chen, Yuan Shi, Weiying Gu, Weidong Ding, Xiao Zheng, Yan Liu, Jingting Jiang, and Zhuojun Zheng
- Subjects
Bispecific antibodies ,Immune checkpoint inhibitors ,Cancer ,Efficacy ,Safety ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. These antibodies demonstrate superior clinical efficacy than monoclonal antibodies, indicating their role as a promising tumor immunotherapy option. Immune checkpoints are also important in tumor immunotherapy. Programmed cell death protein-1 (PD-1) is a widely acknowledged immune checkpoint target with effective anti-tumor activity. PD-1 inhibitors have demonstrated notable therapeutic efficacy in treating hematological and solid tumors; however, more than 50% of patients undergoing this treatment exhibit a poor response. However, ICI-based combination therapies (ICI combination therapies) have been demonstrated to synergistically increase anti-tumor effects and immune response rates. In this review, we compare the clinical efficacy and side effects of BSABs and ICI combination therapies in real-world tumor immunotherapy, aiming to provide evidence-based approaches for clinical research and personalized tumor diagnosis and treatment.
- Published
- 2024
- Full Text
- View/download PDF
3. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
- Author
-
Ming Shi, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Junnian Zheng, and Jiang Cao
- Subjects
Science - Abstract
Abstract Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluate antimyeloma activity in vitro and in vivo. Preclinical results indicate that BC19 CAR specifically recognize target antigens, and BC19 CAR T cells mediate selective killing of BCMA or CD19-positive cancer cells. BC19 CAR T cells also exhibit potent antigen-specific anti-tumor activity in xenograft mouse models. We conduct an open-label, single-arm, phase I/II study of BC19 CAR T cells in 50 patients with R/R MM (ChiCTR2000033567). The primary endpoint was safety. BC19 CAR T cells are well tolerated with grade 3 or higher cytokine release syndrome in 8% of patients and grade 1 neurotoxic events in 4% of patients, which meet the pre-specified primary endpoint. Secondary endpoints include overall response rate (92%), median progression-free survival (19.7 months), median overall survival (19.7 months) and median duration of response (not reached). Our study demonstrates that bispecific BC19 CAR T cells are feasible, safe and effective in treating patients with R/R MM.
- Published
- 2024
- Full Text
- View/download PDF
4. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome
- Author
-
Fei Wang, Silu Cui, Luo Lu, Xiaoliang Shao, Feng Yan, Yaqi Liu, Bai He, Jianfeng Wang, Yang Cao, Yanhua Yue, Yuetao Wang, and Weiying Gu
- Subjects
Dissemination ,Distance ,PET/CT ,Diffuse large B-cell lymphoma ,Prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background 18F-FDG PET/CT provides precise information about dissemination of lymphoma lesions. Dmax, defined as distance between the two lesions that were farthest apart by PET/CT, was found to be a promising predictor of Diffuse large B-cell lymphoma (DLBCL) outcome in a small size of clinical trial data. We analyzed the impact of Dmax on the outcome of a large real-world DLBCL cohort. Methods Data of newly diagnosed DLBCL at the Third Affiliated Hospital of Soochow University were retrospectively collected. Baseline Dmax, clinical data and survival information were recorded. A metabolic parameter, metabolic bulk volume (MBV), was also measured to verify the independent impact of Dmax. Results Optimal cut-off values for Dmax and MBV were 45.34 cm and 21.65 cm3. With a median follow-up of 32 months, Dmax significantly impacted progression-free survival (PFS) and overall survival (OS) in 253 DLBCL patients. For Dmaxlow and Dmaxhigh groups, estimated 3-year OS were 87.0% and 53.8% (p
- Published
- 2023
- Full Text
- View/download PDF
5. Clinical characteristics and prognostic factors of 75 cases with acquired hemophagocytic syndrome
- Author
-
Haonan Yang, Yang Cao, Juan Liu, Yue Liu, Bin Yang, Yun Ling, Yuanjing Fu, Yan Liu, and Weiying Gu
- Subjects
Hemophagocytic syndrome ,Systemic Inflammation Index ,clinical features ,survival analysis ,prognosis ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
ABSTRACTObjectives The study's aim was to enhance awareness of acquired hemophagocytic syndrome (HPS) in adults by analyzing clinical features, and investigating the relationship between factors such as the Systemic Inflammation Index (SII) and the prognosis of HPS.Methods Clinical characteristics, survival data, and prognostic factors of 75 HPS patients admitted to our hospital between January 2012 and October 2022 were analyzed.Results In the high SII group, red blood cells, white blood cells, platelets, neutrophils, fibrinogen, and CD4 + cell activity were higher, and survival time was longer compared to the low SII group. Conversely, total bilirubin and direct bilirubin were higher in the low SII group (P ≤ 0.05). After applying the log-Rank or Breslow tests, HPS patients in the high SII group and those following the HLH-2004 protocol experienced a notably longer survival time. (χ2 = 4.291, P
- Published
- 2023
- Full Text
- View/download PDF
6. Prognostication refinement in NPM1‐mutated acute myeloid leukemia stratified by FLT3‐ITD status with different induction doses of cytarabine
- Author
-
Biao Wang, Xiaoying Hua, Jihong Zhang, Weiying Gu, and Haiqian Li
- Subjects
acute myeloid leukemia ,cytarabine ,FLT3‐ITD ,next‐generation sequencing ,NPM1 ,prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective We aimed to retrospectively discern the heterogeneity of outcomes from clinicopathological characteristics and next‐generation sequencing (NGS) data in adult patients with NPM1‐mutated (NPM1mut) acute myeloid leukemia (AML) induced with standard‐dose (SD, 100–200 mg/m2) and intermediate‐dose (ID, 1000–2000 mg/m2) cytarabine arabinose (Ara‐C). Methods In the entire cohort and FLT3‐ITD subgroups, multivariate Logistic and Cox regression analyses were used to analyze the comprehensive complete remission (cCR) rate after one or two induction cycles, event‐free survival (EFS), and overall survival (OS). Results Among a total of 203 NPM1mut patients evaluable for clinical outcome, 144 (70.9%) received a first SD‐Ara‐C induction and 59 (29.1%) received ID‐Ara‐C induction. Early death was recorded in seven (3.4%) after one or two cycles of induction. Focusing analysis on the NPM1mut/FLT3‐ITD(−) subgroup, independent factors showing inferior outcome were presence of TET2 mutation [cCR rate, OR = 12.82 (95%CI 1.93–85.28), p = 0.008; EFS, HR = 2.92 (95%CI 1.46–5.86), p = 0.003], increasing age [EFS, HR = 1.49 (95%CI 1.10–2.02), p = 0.012 by every 10‐years elevation], white blood cell count ≥60 × 109/L [EFS, HR = 3.30 (95%CI 1.63–6.70), p = 0.001], and ≥4 mutated genes at initial diagnosis [OS, HR = 5.54 (95%CI 1.77–17.33), p = 0.003]. In contrast, when focusing on the NPM1mut/FLT3‐ITD(+) subgroup, factors showing superior outcome were ID‐Ara‐C induction [cCR rate, OR = 0.20 (95%CI 0.05–0.81), p = 0.025; EFS, HR = 0.27 (95%CI 0.13–0.60), p = 0.001] and allo‐transplantation [OS, HR = 0.45 (95%CI 0.21–0.94), p = 0.033]. Factors showing inferior outcome included CD34(+) [cCR rate, OR = 6.22 (95%CI 1.86–20.77), p = 0.003; EFS, HR = 2.01 (95%CI 1.12–3.61), p = 0.020] and ≥5 mutated genes [OS, HR = 2.85 (95%CI 1.33–6.10), p = 0.007]. Conclusion We conclude that TET2(+), age, and white blood cell count convey an outcome risk modulation for AML with NPM1mut/FLT3‐ITD(−), as does CD34 and ID‐Ara‐C induction for NPM1mut/FLT3‐ITD(+). The findings permit re‐stratification of NPM1mut AML into distinct prognostic subsets to guide risk‐adapted individualized treatment.
- Published
- 2023
- Full Text
- View/download PDF
7. Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
- Author
-
Yan Lin, Quan Gu, Shihong Lu, Zengkai Pan, Zining Yang, Yapu Li, Shangda Yang, Yanling Lv, Zhaofeng Zheng, Guohuan Sun, Fanglin Gou, Chang Xu, Xiangnan Zhao, Fengjiao Wang, Chenchen Wang, Shiru Yuan, Xiaobao Xie, Yang Cao, Yue Liu, Weiying Gu, Tao Cheng, Hui Cheng, and Xiaoxia Hu
- Subjects
Stem cells ,Medicine - Abstract
Acute graft-versus-host disease (aGVHD) is a severe complication of allogeneic hematopoietic stem cell transplantation. Hematopoietic dysfunction accompanied by severe aGVHD, which may be caused by niche impairment, is a long-standing clinical problem. However, how the bone marrow (BM) niche is damaged in aGVHD hosts is poorly defined. To comprehensively address this question, we used a haplo-MHC–matched transplantation aGVHD murine model and performed single-cell RNA-Seq of nonhematopoietic BM cells. Transcriptional analysis showed that BM mesenchymal stromal cells (BMSCs) were severely affected, with a reduction in cell ratio, abnormal metabolism, compromised differentiation potential, and defective hematopoiesis-supportive function, all of which were validated by functional assays. We found that ruxolitinib, a selective JAK1/2 inhibitor, ameliorated aGVHD-related hematopoietic dysfunction through a direct effect on recipient BMSCs, resulting in improved proliferation ability, adipogenesis/osteogenesis potential, mitochondria metabolism capacity, and crosstalk with donor-derived hematopoietic stem/progenitor cells. By inhibiting the JAK2/STAT1 pathway, ruxolitinib maintained long-term improvement of aGVHD BMSC function. Additionally, ruxolitinib pretreatment in vitro primed BMSCs to better support donor-derived hematopoiesis in vivo. These observations in the murine model were validated in patient samples. Overall, our findings suggest that ruxolitinib can directly restore BMSC function via the JAK2/STAT1 pathway and, in turn, improve the hematopoietic dysfunction caused by aGVHD.
- Published
- 2023
- Full Text
- View/download PDF
8. Exosomes and cancer immunotherapy: A review of recent cancer research
- Author
-
Yue Cao, Peng Xu, Yangling Shen, Wei Wu, Min Chen, Fei Wang, Yuandong Zhu, Feng Yan, Weiying Gu, and Yan Lin
- Subjects
extracellular vesicle ,exosome ,tumor immune microenvironment ,gastrointestinal cancer ,immunotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
As phospholipid extracellular vesicles (EVs) secreted by various cells, exosomes contain non-coding RNA (ncRNA), mRNA, DNA fragments, lipids, and proteins, which are essential for intercellular communication. Several types of cells can secrete exosomes that contribute to cancer initiation and progression. Cancer cells and the immune microenvironment interact and restrict each other. Tumor-derived exosomes (TDEs) have become essential players in this balance because they carry information from the original cancer cells and express complexes of MHC class I/II epitopes and costimulatory molecules. In the present study, we aimed to identify potential targets for exosome therapy by examining the specific expression and mechanism of exosomes derived from cancer cells. We introduced TDEs and explored their role in different tumor immune microenvironment (TIME), with a particular emphasis on gastrointestinal cancers, before briefly describing the therapeutic strategies of exosomes in cancer immune-related therapy.
- Published
- 2023
- Full Text
- View/download PDF
9. Market Equilibria With Energy Storage as Flexibility Resources
- Author
-
Weiying Gu and Ramteen Sioshansi
- Subjects
Energy storage ,power-system economics ,power-system markets ,power-system operations ,Distribution or transmission of electric power ,TK3001-3521 ,Production of electric energy or power. Powerplants. Central stations ,TK1001-1841 - Abstract
Uncertain and variable real-time availability of renewable generation can increase the need for supply-side flexibility in power systems. Energy storage is a potential source of such flexibility. This paper examines the participation of multiple competing strategic profit-maximizing energy storage in a spot electricity market and its impact on consumers, producers, and market equilibria. To this end, we develop a two-stage stochastic bi-level model that has each energy-storage firm determine its market offers at the upper level to maximize its expected profit. The lower level represents market clearing under scenarios with different flexibility needs. We recast the bi-level model as a single-level optimization. A small illustrative example and larger case study show that energy storage can increase market efficiency and reduce renewable-energy curtailment. We show that energy-storage firms neglecting uncertainty in optimizing their market offers can yield profit losses.
- Published
- 2022
- Full Text
- View/download PDF
10. Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
- Author
-
Yanhua Yue, Yang Cao, Xunyuan Mao, Fei Wang, Peng Fan, Long Qian, Shuxin Guo, Feng Li, Yanting Guo, Tongbing Chen, Yan Lin, Weimin Dong, Yue Liu, Yuhui Huang, and Weiying Gu
- Subjects
multiple myeloma ,patient-derived xenograft ,anlotinib therapy ,tumor angiogenesis ,tumor-associated macrophages ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Multiple myeloma (MM) remains a common hematologic malignancy with a 10-year survival rate below 50%, which is largely due to disease relapse and resistance. The lack of a simple and practical approach to establish myeloma patient-derived xenograft (PDX) hampers translational myeloma research. Here, we successfully developed myeloma PDXs by subcutaneous inoculation of primary mononuclear cells from MM patients following series tumor tissue transplantations. Newly established myeloma PDXs retained essential cellular features of MM and recapitulated their original drug sensitivities as seen in the clinic. Notably, anlotinib therapy significantly suppressed the growth of myeloma PDXs even in bortezomib-resistant model. Anlotinib treatments polarized tumor-associated macrophages from an M2- to an M1-like phenotype, decreased tumor vascular function, and accelerated cell apoptosis in myeloma PDXs. Our preclinical work not only unveiled the potency of anlotinib to overcome bortezomib resistance, but also provided a more practical way to establish MM PDX to facilitate myeloma research.
- Published
- 2022
- Full Text
- View/download PDF
11. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
- Author
-
Yang Cao, Huizhuang Shan, Meng Liu, Jia Liu, Zilu Zhang, Xiaoguang Xu, Yue Liu, Hanzhang Xu, Hu Lei, Miao Yu, Xingming Zhang, Wanting Liu, Zhilei Bu, Zhixiao Fang, Yanjie Ji, Hua Yan, Weiying Gu, and Yingli Wu
- Subjects
Cytology ,QH573-671 - Abstract
Abstract Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor (TKI), has exhibited encouraging antitumor activity in several preclinical and clinical trials, but its effect on MM has not been studied yet. In this study, we found that anlotinib exhibits encouraging cytotoxicity in MM cells, overcomes the protective effect of the bone marrow microenvironment and suppresses tumor growth in the MM mouse xenograft model. We further examined the underlying molecular mechanism and found that anlotinib provokes cell cycle arrest, induces apoptosis and inhibits multiple signaling pathways. Importantly, we identify c-Myc as a novel direct target of anlotinib. The enhanced ubiquitin proteasomal degradation of c-Myc contributes to the cell apoptosis induced by anlotinib. In addition, anlotinib also displays strong cytotoxicity against bortezomib-resistant MM cells. Our study demonstrates the extraordinary anti-MM effect of anlotinib both in vitro and in vivo, which provides solid evidence and a promising rationale for future clinical application of anlotinib in the treatment of human MM.
- Published
- 2021
- Full Text
- View/download PDF
12. Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
- Author
-
Biao Wang, Bin Yang, Yun Ling, Jihong Zhang, Xiaoying Hua, Weiying Gu, and Feng Yan
- Subjects
acute myeloid leukemia ,CD19 ,cytarabine ,KIT ,t(8 ,21) ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract High‐dose cytarabine (Ara‐C) has been reported with increased treatment‐related mortality, whereas few data are available concerning intermediate‐dose Ara‐C for induction of acute myeloid leukemia (AML) with t(8;21) translocation. We retrospectively analyzed factors impacting complete remission (CR), event‐free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS) in 197 adults with t(8;21) AML, of whom 107 cases were induced with intermediate‐dose and 90 with standard‐dose Ara‐C (as part of 3 + 7 protocol). After a single induction course, the overall CR rate was 87.6% (170/194), with a significant difference between the standard‐dose (83/105, 79.0%) and intermediate‐dose (87/89, 97.8%) groups (p
- Published
- 2021
- Full Text
- View/download PDF
13. A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China
- Author
-
Ziyuan Shen, Yingliang Jin, Qian Sun, Shuo Zhang, Xi Chen, Lingling Hu, Chenlu He, Ying Wang, Qinhua Liu, Hao Zhang, Xin Liu, Ling Wang, Jun Jiao, Yuqing Miao, Weiying Gu, Fei Wang, Chunling Wang, Yuye Shi, Jingjing Ye, Taigang Zhu, Cai Sun, Xuguang Song, Linyan Xu, Dongmei Yan, Haiying Sun, Jiang Cao, Depeng Li, Zhenyu Li, Zhao Wang, Shuiping Huang, Kailin Xu, and Wei Sang
- Subjects
hemophagocytic lymphohistiocytosis ,adult ,multicenter ,prognostic model ,stratification ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder with rapid progression and poor survival. Individual treatment strategy is restricted, due to the absence of precise stratification criteria. In this multicenter retrospective study, we aimed to develop a feasible prognostic model for adult HLH in China. A total of 270 newly diagnosed patients of adult HLH were retrieved from the Huaihai Lymphoma Working Group (HHLWG), of whom 184 from 5 medical centers served as derivation cohort, and 86 cases from 3 other centers served as validation cohort. X-Tile program and Maxstat analysis were used to identify optimal cutoff points of continuous variables; univariate and multivariate Cox analyses were used for variable selection, and the Kaplan–Meier curve was used to analyze the value of variables on prognosis. The C-index, Brier Score, and calibration curve were used for model validation. Multivariate analysis showed that age, creatinine, albumin, platelet, lymphocyte ratio, and alanine aminotransferase were independent prognostic factors. By rounding up the hazard ratios from 6 significant variables, a maximum of 9 points was assigned. The final scoring model of HHLWG-HPI was identified with four risk groups: low risk (≤3 pts), low-intermediate risk (4 pts), high-intermediate risk (5-6 pts), and high risk (≥7 pts), with 5-year overall survival rates of 68.5%, 35.2%, 21.3%, and 10.8%, respectively. The C-indexes were 0.796 and 0.758 in the derivation and validation cohorts by using a bootstrap resampling program. In conclusion, the HHLWG-HPI model provides a feasible and accurate stratification system for individualized treatment strategy in adult HLH.
- Published
- 2022
- Full Text
- View/download PDF
14. The Addition of Ferritin Enhanced the Prognostic Value of International Prognostic Index in Diffuse Large B‐Cell Lymphoma
- Author
-
Ziyuan Shen, Shuo Zhang, Meng Zhang, Lingling Hu, Qian Sun, Chenlu He, Dongmei Yan, Jingjing Ye, Hao Zhang, Ling Wang, Weiying Gu, Yuqing Miao, Qinhua Liu, Changli Ouyang, Junfeng Zhu, Chunling Wang, Taigang Zhu, Shuiping Huang, and Wei Sang
- Subjects
ferritin ,DLBCL ,International Prognostic Index ,prognosis ,nomogram ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous non-Hodgkin lymphoma, and the prognosis of DLBCL patients is widely affected by multivariables. Clinical-factors-based prognostic systems stratify the prognosis of DLBCL with certain limitations, and the value of ferritin on the prognosis of DLBCL is unclear. In this study, 225 cases were retrieved from 4 centers of Huaihai Lymphoma Working Group (HHLWG) as the derivation cohort, and 66 cases were from the other 6 centers of HHLWG as external validation cohort. X-Tile program divided ferritin into three groups when applying 175.00 and 391.90 μg/L as the optimal cutoff points. Based on multivariable analysis, ferritin appeared to be a stronger predictor. A total of three variables (ferritin, age, and lactate dehydrogenase) were included for the development of the nomogram. The C-indexes were 0.73 and 0.70 in the derivation and validation cohort, and the calibration curve showed the consistency between the nomogram prediction and the actual observation. In conclusion, Ferritin-based nomogram enhanced the prognostic value of IPI in DLBCL.
- Published
- 2022
- Full Text
- View/download PDF
15. Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China
- Author
-
Ziyuan Shen, Ling Wang, Bingpei Zhang, Tianci Li, Dashan Li, Chenlu He, Yuhao Xue, Ying Wang, Bingzong Li, Qinhua Liu, Hao Zhang, Weiying Gu, Fei Wang, Chunling Wang, Yuye Shi, Jingjing Ye, Taigang Zhu, Yuqing Miao, Shuiping Huang, and Wei Sang
- Subjects
CD5-positive ,DLBCL ,nomogram ,prognosis ,validation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundCD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a rare subtype of DLBCL with invasive clinical features and poor prognosis. Current clinical variables based on prognostic systems for DLBCL are inadequate to accurately stratify the prognosis of CD5+ DLBCL.MethodsA total of 195 CD5+ DLBCL patients were retrospectively recruited from nine centers in Huaihai Lymphoma Working Group. MaxStat analysis was used to identify optimal cutoff points for continuous variables; univariable and multivariable Cox analyses were used for variable selection; Kaplan–Meier curve was used to analyze the value of variables on prognosis; and C-index, Brier score, and decision curve analysis were measured for predicting model performance.ResultsThe derivation and validation cohorts consisted of 131 and 64 patients. Of the whole cohort, median age at diagnosis was 61 years, of whom 100 (51.28%) were males and the 5‐year overall survival rate was 42.1%. MYC, BCL-2, and the coexpression of MYC/BCL-2 could distinguish the survival of CD5+ DLBCL. Multivariable analysis showed that age, IPI, red blood cell count, neutrophil count, MYC expression, and hepatosplenomegaly were independent predictors, and the prognostic nomogram was developed. The C‐index of the nomogram was 0.809 in the derivation and 0.770 in the validation cohort. Decision curve analysis proved that compared with IPI, the specific nomogram showed a better identification in CD5+ DLBCL.ConclusionThe proposed nomogram provided a valuable tool for prognosis prediction in patients with CD5+ DLBCL.
- Published
- 2021
- Full Text
- View/download PDF
16. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis
- Author
-
Yang Cao, Yue Liu, Limei Shang, Wei Wei, Yangling Shen, Quan Gu, Xiaobao Xie, Weimin Dong, Yan Lin, Yanhua Yue, Fei Wang, and Weiying Gu
- Subjects
Decitabine ,ATRA ,miR-34a ,MYCN ,Acute myeloid leukemia ,Therapeutics. Pharmacology ,RM1-950 - Abstract
This study aimed to investigate the efficacy and mechanism of decitabine (DAC) and all-trans retinoic acid (ATRA) in elderly acute myeloid leukemia (AML) patients and cultured cells. Our clinical trial enrolled 36 elderly patients who were judged ineligible for conventional chemotherapy, receiving DAC and ATRA regimen (DAC 20 mg/m2 days 1–5; ATRA 20 mg/m2 days 4–28 in the first cycle and days 1–28 in the subsequent cycle). Treated with a median of 3 cycles (range 1–6), 44.4 % of patients achieved complete remission (CR), 11.1 % achieved CR with incomplete peripheral count recovery (CRi) and 13.9 % achieved partial remission (PR). The median overall survival (OS) was 12.1 months; the 1-year and 2-year OS rates were 49.6 % and 17.2 %. In addition, our in vitro studies indicated that the antineoplastic activities of DAC and ATRA mutually reinforced, which induced growth inhibition, cell cycle arrest and apoptosis of AML cells. Meanwhile, we found DAC and ATRA inhibited DNMT1, activated miR-34a via promoter hypomethylation, down-regulated its target MYCN and thus exerted a synergistic antineoplastic effect. In conclusion, DAC plus ATRA regimen might be effective and well-tolerated for elderly patients partially through modulating miR-34a/MYCN axis.
- Published
- 2020
- Full Text
- View/download PDF
17. Prognostic Significance of MiRNA in Patients with Diffuse Large B-Cell Lymphoma: a Meta-Analysis
- Author
-
Zhuojun Zheng, Xiaodong Li, Yuandong Zhu, Weiying Gu, Xiaobao Xie, and Jingting Jiang
- Subjects
Diffuse large B-cell lymphoma ,Meta-analysis ,Relapse free survival ,Progression free survival ,MiRNA ,Physiology ,QP1-981 ,Biochemistry ,QD415-436 - Abstract
Introduction: This pooled analysis study aimed to reveal the prognostic relevance of microRNAs (miRNAs) in patients with diffuse large B-cell lymphoma (DLBCL). Materials and Methods: We examined the impact of miRNAs on clinical outcome. Eligible studies were identified and quality assessed using multiple search strategies. Data were extracted from included studies which correlated survival with expression of miRNAs (serum or tissue). Results: We pooled proper studies, and combined the hazard ratios with 95% confidence intervals to estimate strength of the correlations. There were 18 studies including 1950 patients with DLBCL eligible for pooled analysis. We found significant combined HRs for poor overall survival for high expression of miR-21 and low expression of miR-224 in tumor tissue, but for favorable relapse free survival for high expression of miR-21 in serum. Progression free survival was shortened in patients with low expression of miR-199a/b, miR-146b-5p, miR-224 and high expression of miR-222. Conclusion: MiRNAs may act as independent prognostic factors in patients with DLBCL, and useful in risk stratification.
- Published
- 2016
- Full Text
- View/download PDF
18. Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia
- Author
-
Yan Lin, Rongrong Lin, Guangquan Zhou, Yue Liu, Weimin Dong, Yang Cao, Xiaobao Xie, and Weiying Gu
- Subjects
Medicine (General) ,R5-920 - Abstract
Primary myelofibrosis (PMF) is a type of cloned myeloproliferative neoplasm stemming from haematopoietic stem cells, and tends to transform to acute myeloid leukaemia (AML) in approximately 10–20% of cases over a 10-year period. The transformation into AML has a poor prognosis, with a median overall survival of only 2.6 months in patients receiving supportive treatment. To date, treatment of AML transformation remains poor. The case of a 58-year-old female patient with AML transformed from PMF, who was treated with decitabine combined with all-trans retinoic acid, is reported. The patient had complete remission and a 17-month overall survival from initial diagnosis of transformed AML, with tolerated haematologic toxicity during the treatment period.
- Published
- 2019
- Full Text
- View/download PDF
19. Acute thrombosis in superior mesenteric artery as first symptom in a AML patient
- Author
-
Yan Liu, Xangshan Chao, Weiying Gu, Xiaoying Hua, and Ning Xu
- Subjects
Medicine (General) ,R5-920 - Abstract
Yan Liu1, Xangshan Chao1, Weiying Gu1, Xiaoying Hua1, Ning Xu21Department of Hematology, The Third Affiliated Hospital, Suzhou University, Changzhou, China; 2Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Lund, SwedenAbstract: It is well known that acute leukemia may accompany thromboembolic events; even severe thrombocytopenia does not prevent thrombosis. Coagulation dysfunction is the major pathophysiological background for thromboembolism in these patients. Most thromboembolism is localized in venous vessels in acute leukemic patients and it happens rarely in the artery. We report a case of acute thrombosis in the superior mesenteric artery as the first symptom in a patient suffering from acute myeloid leukemia (FAB M4).Keywords: acute leukemia, thromboembolism, pathogenesis
- Published
- 2008
20. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.
- Author
-
Feng Zhi, Xiangshan Cao, Xiaobao Xie, Biao Wang, Weimin Dong, Weiying Gu, Yun Ling, Rong Wang, Yilin Yang, and Yan Liu
- Subjects
Medicine ,Science - Abstract
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The disease is characterized by various cytogenetic and molecular abnormalities with distinct prognoses and gene expression profiles. Emerging evidence has suggested that circulating microRNAs (miRNAs) could serve as noninvasive biomarkers for cancer detection; however, little is known about circulating miRNA profiles in AML patients. In this study, a genome-wide serum miRNA expression analysis was performed using Solexa sequencing for initial screen, followed by validation with real-time PCR assays. The analysis was conducted on training and verification sets of serum samples from 140 newly diagnosed AML patients and 135 normal adult donors. After a two-phase selection and validation process, 6 miRNAs, miR-10a-5p, miR-93-5p, miR-129-5p, miR-155-5p, miR-181b-5p and miR-320d, were found to have significantly different expression levels in AML compared with control serum samples. Furthermore, unsupervised clustering analysis revealed the remarkable ability of the 6-miRNA profile to differentiate between AML patients and normal controls. The areas under the ROC curve for the selected miRNAs ranged from 0.8129 to 0.9531. More importantly, miR-181b-5p levels in serum were significantly associated with overall survival. These data demonstrated that the expression patterns of circulating miRNAs were systematically altered in AML and miR-181b-5p may serve as a predictor for overall survival in AML patients.
- Published
- 2013
- Full Text
- View/download PDF
21. High expression of miR-107 and miR-17 predicts poor prognosis and guides treatment selection in acute myeloid leukemia
- Author
-
Yue Liu, Yang Cao, Xiaojun Yang, Huijuan Chen, Haonan Yang, Yan Liu, and Weiying Gu
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2023
22. Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab
- Author
-
Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, and Weiying Gu
- Subjects
Hematology ,General Medicine - Published
- 2023
23. Clinical significance of plasma PD-L1+ exosomes in the management of diffuse large B cell lymphoma
- Author
-
Peng Xu, Juan Liu, Huijuan Chen, Limei Shang, Fei Wang, Yuandong Zhu, Yanting Guo, Feng Li, Feng Yan, Xiaobao Xie, Liang Li, Weiying Gu, and Yan Lin
- Subjects
Hematology ,General Medicine - Published
- 2023
24. Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study
- Author
-
Yuan, Shi, Weidong, Ding, Weiying, Gu, Yangling, Shen, Haiqian, Li, Zhuojun, Zheng, Xiao, Zheng, Yan, Liu, and Yun, Ling
- Subjects
Signaling Lymphocytic Activation Molecule Family ,Antineoplastic Combined Chemotherapy Protocols ,Immunology ,Leukocytes, Mononuclear ,Humans ,Reproducibility of Results ,Immunology and Allergy ,Lymphoma, Large B-Cell, Diffuse ,Cell Biology ,Prognosis ,Biomarkers - Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common invasive type of non-Hodgkin lymphoma. Cell-of-origin (COO) classification is related to patients’ prognoses. Primary drug resistance in treatment for DLBCL has been observed. The specific serum biomarkers in these patients who suffer from relapsed and refractory (R/R)-DLBCL remains unclear. In the current study, using single-cell RNA sequencing (scRNA-seq) and mass cytometry (CyTOF), we determined and verified immune cell biomarkers at the mRNA and protein levels in single-cell resolution from 18 diagnostic PBMC specimens collected from patients with R/R DLBCL. As controls, 5 PBMC specimens from healthy volunteers were obtained. We identified a panel of 35 surface marker genes for the features of R/R DLBCL unique cell cluster by scRNA-seq of 8 R/R DLBCL patient samples and validated its efficiency in an external cohort consisting of 10 R/R DLBCL patients by CyTOF. The cell clustering and dimension reduction were compared among R/R DLBCL samples in CyTOF Space with COO as well as the C-MYC expression designation. Immune cells from each patient occupied unique regions in the 32-dimensional phenotypic space with no apparent clustering of samples into discrete subtypes. Significant heterogeneity observed in subgroups was mainly attributed to individual differences among samples and not to expression differences in a single, homogeneous immune cell subpopulation. The marker panel showed reliability in labeling R/R DLBCL without any influence from COO stratification and C-MYC expression designation. Furthermore, we compared all the markers between R/R DLBCL and normal samples. A total of 12 biomarkers were significantly overexpressed in R/R DLBCL relative to the normal samples. Therefore, we further optimized the diagnostic biomarker panel of R/R DLBCL comprising CD82, CD55, CD36, CD63, CD59, IKZF1, CD69, CD163, CD14, CD226, CD84, and CD31. In summary, we developed a novel set of biomarkers for the diagnoses of patients with R/R DLBCL. Detections procedures at single-cell resolution provide precise biomarkers, which may substantially overcome intertumoral and intratumoral heterogeneity among primary samples. The findings confirmed that each case was unique and may comprise multiple, genetically distinct subclones.
- Published
- 2022
25. Antitumor Activity of Ethyl Acetate Extraction of Wikstroemia chamaedaphne: Cell Cycle Arrest and Apoptosis-Inducing Activity in Melanoma Cells
- Author
-
Jianyong Zhu, Yuan Li, Chunyan Zhang, Yiwen Nie, Ruifeng Zhang, Xiaoxiang Zhai, Yanjuan Duan, Wei Fan, Weiying Gu, Kourong Shi, and Lan Luo
- Subjects
Pharmacology ,Organic Chemistry ,Drug Discovery ,Plant Science - Published
- 2022
26. Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma
- Author
-
Wei Sang, Yuhan Ma, Xiangmin Wang, Yuanyuan Ma, Ziyuan Shen, Weiying Gu, Fei Wang, Jingjing Ye, Cuijuan Zhang, Yuqing Miao, Chuanhai Xu, Qinhua Liu, Bingzong Li, Jian Tu, Chunling Wang, Yuye Shi, Su’an Sun, Dongmei Yan, Xuguang Song, Cai Sun, Yang Shao, Linyan Xu, Zhenyu Li, Dongshen Ma, Kailin Xu, Ken H. Young, and Hui Liu
- Subjects
Proto-Oncogene Proteins c-bcl-2 ,Myeloid Differentiation Factor 88 ,Humans ,Surgery ,Genomics ,Lymphoma, Large B-Cell, Diffuse ,Tumor Suppressor Protein p53 ,Anatomy ,CD5 Antigens ,Prognosis ,Aged ,Retrospective Studies ,Pathology and Forensic Medicine - Abstract
De novo CD5 + diffuse large B-cell lymphoma (DLBCL) has poor survival in the era of immunochemotherapy. Accurate gene-based typing and prognostic stratification can enhance the development of effective individualized treatments. Therefore, we conducted a multicenter retrospective study to evaluate the clinicopathologic characteristics, genomic profiles, and prognostic parameters of 61 patients with CD5 + DLBCL and 60 patients with CD5 - DLBCL, with the goal of facilitating accurate prognostic stratification and potential individualized treatment strategies. Compared with patients with CD5 - DLBCL, older age, advanced stage, higher incidence of central nervous system involvement, and MYC/BCL-2 and p53 overexpression were more prevalent in CD5 + DLBCL. Most patients with CD5 + DLBCL had lymph nodes with non-germinal center B-cell-like or activated B-cell-like subtype according to immunohistochemistry or Lymph2Cx assay. Next-generation sequencing showed that the proportion of MCD subtype (based on the co-occurrence of MYD88 and CD79B mutations) in the CD5 + DLBCL cohort was higher than that in the CD5 - DLBCL cohort (54.2% vs. 13.0%, P =0.005). Compared with the CD5 - cohort, CD5 + DLBCL patients showed poor 5-year overall survival (70.9% vs. 39.0%, P0.001). Kaplan-Meier survival analysis indicated that cell of origin, MYC/BCL-2, p53, and BCL-6 expression did not have a prognostic impact on patients with CD5 + DLBCL. Multivariate analysis showed that age above 76 years, advanced stage, higher incidence of central nervous system involvement, and hypoalbuminemia were independent factors for poor prognosis in CD5 + DLBCL patients. In summary, CD5 + DLBCL displays poor prognosis, distinctive clinicopathologic characteristics and predominant genetic features of activated B-cell-like and MCD subtypes with worse survival outcome.
- Published
- 2022
27. Corrigendum to 'Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy' [Leuk. Res. 122 (2022) 106949]
- Author
-
Yanhua Yue, Yang Cao, Fei Wang, Naidong Zhang, Ziwei Qi, Xunyuan Mao, Shuxin Guo, Feng Li, Yanting Guo, Yan Lin, Weimin Dong, Yuhui Huang, and Weiying Gu
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2023
28. Disparity analysis and prognostic value of pretreatment whole blood <scp>Epstein‐Barr</scp> virus <scp>DNA</scp> load and Epstein‐Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group
- Author
-
Weiying Gu, Taigang Zhu, Wei Sang, Yingliang Jin, Qinhua Liu, Fei Wang, Ziyuan Shen, Chenlu He, Fei Li, Manyu Dong, Ying Wang, Mingkang Yao, Lingling Hu, Hao Zhang, Ting Yin, and Shuiping Huang
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,Follicular lymphoma ,medicine.disease_cause ,medicine.disease ,Epstein–Barr virus ,Virus ,Lymphoma ,Multicenter study ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,business ,Viral load ,Whole blood - Abstract
Elevated Epstein-Barr virus (EBV) DNA load is common in lymphomas. However, it remains unclear whether the disparity in viral load and its prognostic value in lymphomas are correlated with Epstein-Barr encoding region (EBER) status. In this retrospective multicenter study, we collected the data of pretreatment whole blood EBV DNA (pre-EBV DNA) and EBER status and evaluated their disparity and prognostic values in lymphomas. A total of 454 lymphoma patients from December 2014 to August 2020 were retrospectively retrieved. Mann-Whitney U test, Kruskal-Wallis test and Bonferroni's adjustment were used to explore the disparity of EBV DNA and EBER status in lymphomas. Time-dependent receiver operating characteristic analysis and MaxStat analysis were used to determine optimal cutoff points of pre-EBV DNA load. Univariable and multivariable Cox proportional hazards models were established for the estimation of prognostic factors. The positive rate of EBV DNA in natural killer T-cell lymphoma (NKTL) patients was higher than that in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) patients, and the median positive pre-EBV copy number of NKTL was also higher than that of FL and DLBCL. EBV DNA could clearly distinguish the prognosis of DLBCL, NKTL, HL and peripheral T-cell lymphoma, and the integration of EBER status and EBV DNA could differentiate the prognosis of HL patients. Multivariable results revealed that pre-EBV DNA load had an effect on the prognosis of NKTL, FL and DLBCL. The status of pre-EBV DNA and EBER were disparate. Whole blood pre-EBV DNA predicted the prognosis of lymphomas, and the combination of EBV and EBER status could differentiate the prognosis of HL.
- Published
- 2021
29. Pharmacokinetic, efficacy and safety evaluation of B‐domain‐deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A
- Author
-
Xielan Zhao, Wenqian Li, Feng'e Yang, Weiying Gu, Xiaojing Zeng, Liangzhi Xie, Wenlin Gai, Ming Xu, Hui Bi, Ziqiang Yu, Jing Sun, Ying Feng, Feng Xue, Changcheng Zheng, and Renchi Yang
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Haemophilia A ,Hemorrhage ,030204 cardiovascular system & hematology ,Hemophilia A ,Haemophilia ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Internal medicine ,Breakthrough bleeding ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Adverse effect ,Blood Coagulation ,Genetics (clinical) ,Hemostasis ,Factor VIII ,business.industry ,Incidence (epidemiology) ,Hematology ,General Medicine ,medicine.disease ,Confidence interval ,Treatment Outcome ,medicine.symptom ,business ,030215 immunology - Abstract
Introduction SCT800 is a recombinant human B-domain-deleted coagulation factor VIII (BDDrFVIII) developed in China. Aim To evaluate the repeat pharmacokinetics (PKs), efficacy, and safety of SCT800 in previously treated Chinese adolescent and adult patients with severe haemophilia A. Methods A phase III, multicentre, prospective, open-label, single-arm trial was conducted at 12 medical centres. Subjects received treatment for 24 weeks. PKs were assessed at the initial and repeated dosing 24 weeks later. The primary endpoint was annualized bleeding rate (ABR). Breakthrough bleeding episodes and inhibitor development were assessed. Results A total of 71 of 73 patients completed the study, and 18 were enrolled for the repeat PK investigation. Total exposure was 5643 exposure days. Overall, SCT800 showed comparable repeat PK profiles. The total ABR was 2.82 (95% confidence interval 2.01-3.96). During prophylaxis, 43.8% of patients had no bleeding episodes. The majority (89.4%) of bleeding episodes were controlled with 1-2 injections of SCT800, the success rate (defined as 'excellent' or 'good' haemostatic response) for the treatment of bleeding episodes was 92.6%. The incidence of treatment-related adverse events was 53.4%. Drug-related AE incidence was 4.1%. The observed AEs were similar to those of other coagulation factor VIII, but lower in frequency. No subject developed an inhibitor, and no other safety concerns were identified. Conclusions SCT800 has robust PK characteristics, and is safe and efficacious for the prophylaxis and treatment of bleeding episodes in previously treated adolescent and adult patients with severe haemophilia A.
- Published
- 2021
30. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group
- Author
-
Sha, Ma, Bingpei, Zhang, Tianyi, Lu, Dashan, Li, Tianci, Li, Ziyuan, Shen, Chenlu, He, Ying, Wang, Bingzong, Li, Hao, Zhang, Weiying, Gu, Chunling, Wang, Jingjing, Ye, Taigang, Zhu, Yuqing, Miao, Ling, Wang, Shuiping, Huang, Qinhua, Liu, and Wei, Sang
- Subjects
Survival Rate ,Nutrition Assessment ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Prognosis ,Retrospective Studies - Abstract
CD5-positive diffuse large B-cell lymphoma (DLBCL) is a clinically rare subtype of DLBCL with aggressive clinical manifestations and a poor prognosis. It has been demonstrated that the prognostic nutritional index (PNI), an indicator of nutritional status and systemic inflammation, is a significant prognostic factor for several types of lymphoma. The objective of this multicenter retrospective study was to explore the prognostic value of the PNI in patients with CD5-positive DLBCL.In total, 207 patients with CD5-positive DLBCL were recruited from 11 centers of the Huaihai Lymphoma Working Group. Maximally selected rank statistics analysis was used to identify optimal cutoff points for the PNI. A Cox proportional hazards model was used for univariable and multivariable analyses. Kaplan-Meier curves were used to calculate survival rates and draw survival curves, and the log-rank test was used to compare differences between groups.The median age at diagnosis was 61 years, and the 5-year overall survival rate was 47.5%. According to the maximally selected rank statistics analysis, a score of 49.7 was the optimal cutoff point for the PNI. Subgroup analysis showed that the PNI could re-stratify patients in BCL-2-negative, MYC-negative, high-intermediate-risk and high-risk International Prognostic Index, BCL-6-positive and BCL-6-negative, high Ki-67 score (≥0.9), Ann Arbor stage III/IV, Eastern Cooperative Oncology Group performance status ≥2, and germinal center B subgroups. Multivariable analysis revealed that PNI, age, Eastern Cooperative Oncology Group performance status, albumin level, and red blood cell count were independent prognostic factors for CD5-positive DLBCL.The PNI was a significant prognostic indicator for CD5-positive DLBCL and was able to re-stratify the prognosis for clinicopathologic subgroups of patients with CD5-positive DLBCL.
- Published
- 2022
31. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
- Author
-
Ying Wang, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu, Hujun Li, Bin Pan, Wei Chen, Xiaoming Fei, Chunling Wang, Xiaobao Xie, Liang Yu, Gang Wang, Huizhong Li, Guangjun Jing, Hai Cheng, Feng Zhu, Haiying Sun, Wei Sang, Depeng Li, Zhenyu Li, Junnian Zheng, and Kailin Xu
- Subjects
Cancer Research ,Neoplasm, Residual ,Receptors, Chimeric Antigen ,Oncology ,T-Lymphocytes ,Antigens, CD19 ,Humans ,Multiple Myeloma ,Immunotherapy, Adoptive ,Lymphoma, Follicular ,Follow-Up Studies - Abstract
PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells induced high response rates in patients with relapsed or refractory (R/R) multiple myeloma (MM), but long-term outcomes have not been assessed yet. PATIENTS AND METHODS In this single-arm, phase II trial, patients with R/R MM received a combination of anti-BCMA CAR T cells and anti-CD19 CAR T cells at a dose of 1 × 106 cells/kg, after receiving a conditioning chemotherapy consisting of cyclophosphamide and fludarabine. The overall response, long-term outcomes, and safety were assessed, as were their associations with clinical and disease characteristics. RESULTS Of 69 enrolled patients, 62 received the combined infusion of anti-BCMA and anti-CD19 CAR T cells with a median follow-up of 21.3 months. The overall response rate was 92% (57/62), and complete response or better was observed in 37 patients (60%). Minimal residual disease–negativity was confirmed in 77% (43/56) of the patients with available minimal residual disease detection. The estimated median duration of response was 20.3 months (95% CI, 9.1 to 31.5). The median progression-free survival was 18.3 months (95% CI, 9.9 to 26.7), and the median overall survival was not reached. Patients with extramedullary disease had significantly inferior survival. Fifty-nine patients (95%) had cytokine release syndrome, with 10% grade 3 or higher. Neurotoxic events occurred in seven patients (11%), including 3% grade 3 or higher. Late adverse effects were rare, except for B-cell aplasia, hypogammaglobulinemia, and infections. CONCLUSION The combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with R/R MM, with a median progression-free survival of 18.3 months and a manageable long-term safety profile.
- Published
- 2022
32. Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy
- Author
-
Yanhua, Yue, Yang, Cao, Fei, Wang, Naidong, Zhang, Ziwei, Qi, Xunyuan, Mao, Shuxin, Guo, Feng, Li, Yanting, Guo, Yan, Lin, Weimin, Dong, Yuhui, Huang, and Weiying, Gu
- Subjects
Cancer Research ,Apoptosis ,Hematology ,Bortezomib ,Disease Models, Animal ,Oncology ,Drug Resistance, Neoplasm ,Cell Line, Tumor ,Tumor Microenvironment ,Animals ,Humans ,Heterografts ,Neoplasm Recurrence, Local ,Multiple Myeloma - Abstract
Multiple myeloma (MM) remains an incurable hematologic malignancy due to its frequent drug resistance and relapse. Cluster of Differentiation 47 (CD47) is reported to be highly expressed on MM cells, suggesting that the blockade of CD47 signaling pathway could be a potential therapeutic candidate for MM. In this study, we developed a bortezomib-resistant myeloma patient-derived xenograft (PDX) from an extramedullary pleural effusion myeloma patient sample. Notably, anti-CD47 antibody treatments significantly inhibited tumor growth not only in MM cell line-derived models, including MM.1S and NCI-H929, but also in the bortezomib-resistant MM PDX model. Flow cytometric data showed that anti-CD47 therapy promoted the polarization of tumor-associated macrophages from an M2- to an M1-like phenotype. In addition, anti-CD47 therapy decreased the expression of pro-angiogenic factors, increased the expression of anti-angiogenic factors, and improved tumor vascular function, suggesting that anti-CD47 therapy induces tumor vascular normalization. Taken together, these data show that anti-CD47 antibody therapy reconditions the tumor immune microenvironment and inhibits the tumor growth of bortezomib-resistant myeloma PDX. Our findings suggest that CD47 is a potential new target to treat bortezomib-resistant MM.
- Published
- 2022
33. A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China
- Author
-
Ziyuan Shen, Yingliang Jin, Qian Sun, Shuo Zhang, Xi Chen, Lingling Hu, Chenlu He, Ying Wang, Qinhua Liu, Hao Zhang, Xin Liu, Ling Wang, Jun Jiao, Yuqing Miao, Weiying Gu, Fei Wang, Chunling Wang, Yuye Shi, Jingjing Ye, Taigang Zhu, Cai Sun, Xuguang Song, Linyan Xu, Dongmei Yan, Haiying Sun, Jiang Cao, Depeng Li, Zhenyu Li, Zhao Wang, Shuiping Huang, Kailin Xu, and Wei Sang
- Subjects
Adult ,Lymphoma ,Immunology ,multicenter ,RC581-607 ,Prognosis ,Lymphohistiocytosis, Hemophagocytic ,Survival Rate ,stratification ,hemophagocytic lymphohistiocytosis ,Immunology and Allergy ,prognostic model ,Humans ,Immunologic diseases. Allergy ,Proportional Hazards Models ,Retrospective Studies - Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder with rapid progression and poor survival. Individual treatment strategy is restricted, due to the absence of precise stratification criteria. In this multicenter retrospective study, we aimed to develop a feasible prognostic model for adult HLH in China. A total of 270 newly diagnosed patients of adult HLH were retrieved from the Huaihai Lymphoma Working Group (HHLWG), of whom 184 from 5 medical centers served as derivation cohort, and 86 cases from 3 other centers served as validation cohort. X-Tile program and Maxstat analysis were used to identify optimal cutoff points of continuous variables; univariate and multivariate Cox analyses were used for variable selection, and the Kaplan–Meier curve was used to analyze the value of variables on prognosis. The C-index, Brier Score, and calibration curve were used for model validation. Multivariate analysis showed that age, creatinine, albumin, platelet, lymphocyte ratio, and alanine aminotransferase were independent prognostic factors. By rounding up the hazard ratios from 6 significant variables, a maximum of 9 points was assigned. The final scoring model of HHLWG-HPI was identified with four risk groups: low risk (≤3 pts), low-intermediate risk (4 pts), high-intermediate risk (5-6 pts), and high risk (≥7 pts), with 5-year overall survival rates of 68.5%, 35.2%, 21.3%, and 10.8%, respectively. The C-indexes were 0.796 and 0.758 in the derivation and validation cohorts by using a bootstrap resampling program. In conclusion, the HHLWG-HPI model provides a feasible and accurate stratification system for individualized treatment strategy in adult HLH.
- Published
- 2021
34. Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia
- Author
-
Yang Cao, Yue Liu, Limei Shang, Huijuan Chen, Yanhua Yue, Weimin Dong, Yanting Guo, Haonan Yang, Xiaojun Yang, Yan Liu, Weiying Gu, and Xiaoying Zhang
- Subjects
Leukemia, Myeloid, Acute ,MicroRNAs ,Oncology ,Gene Expression Regulation, Leukemic ,Recurrence ,Fibrinogen ,Humans ,Surgery ,Hematology ,General Medicine ,Prognosis - Abstract
Background The clinical significance of miR-17 in patients with acute myeloid leukemia (AML) remains unknown. Methods Real-time quantitative reverse transcription-polymerase chain reaction (qPCR) was performed to detect the miR-17 expression in 115 de novo AML patients, 31 patients at complete remission (CR) time, 8 patients at relapse time and 30 normal controls. Results MiR-17 was upregulated in de novo AML compared with normal controls. Patients with high expression of miR-17 had less CEBPA double mutation, less favorable ELN-risk and lower CR rate. The level of miR-17 was significantly decreased at CR phase and was returned to primary level even higher when in relapse phase. In addition, Cox regression analysis revealed that miR-17 expression retained independent prognostic significance for overall survival (OS). Moreover, the gene-expression profile analysis of miR-17 in AML obtained from TCGA database was involved in multiple biological functions and signal pathways. Among the differential expressed genes (DEGs), we identified FGL2, PLAUR, SLC2A3, GPR65, CTSS, TLR7, S1PR3, OGFRL1, LILRB1, IL17RA, SIGLEC10, SLAMF7, PLXDC2, HPSE, TCF7 and MYCL as potential direct targets of miR-17 according to in silico analysis. Conclusions High expression of miR-17 in de novo AML patients pointed to dismal clinical outcome and disease recurrence, which could serve as novel prognostic biomarker for AML patients.
- Published
- 2021
35. Regulation Effects of Circular RNA CircPVT1 and miR-125b on NF-κB Signal Pathway in Childhood ALL
- Author
-
Yongqing Jia, Weiying Gu, and Huixian Hu
- Subjects
Chemistry ,Cell growth ,Cell ,NF-kappa B ,RNA ,NF-κB ,RNA, Circular ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,General Biochemistry, Genetics and Molecular Biology ,Signal pathway ,Cell biology ,chemistry.chemical_compound ,MicroRNAs ,medicine.anatomical_structure ,Real-time polymerase chain reaction ,Circular RNA ,medicine ,Humans ,Signal transduction ,Cell Proliferation ,Signal Transduction - Abstract
Background CircPVT1's effects and mechanisms of acute lymphoblastic leukemia were explored in this research. Methods Real-time fluorescent quantitative PCR was utilized to test circPVT1 and miR-125b in ALL samples and ALL cell systems. Dual luciferase reporter assay verified the combination of circPVT1 and miR-125b. We utilized circPVAT1 as well as miR-125b's over-expression and low-expression to prove their influence on cell proliferation and invading. Results We found that more expression of circPVT1 occurred in ALL samples and ALL cell systems. CircPVT1 over-expression promoted ALL cell proliferation and migration besides invading. CircPVT1 low expression inhibited ALL cell proliferation and migration besides invading. MiR-125b was a target combination of circPVT1. CircPVT1 was able to enhance NF-κB signal pathway's expression through reducing miR-125b. Conclusions CircPVT2 can promote ALL cell proliferation and invading through miR-125b modulation of NF-κB, which would be one new potential target for ALL therapy.
- Published
- 2021
36. Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China
- Author
-
Yuqing Miao, Wei Sang, Ling Wang, Chunling Wang, Shuiping Huang, Taigang Zhu, Bingpei Zhang, Weiying Gu, Hao Zhang, Yuye Shi, Fei Wang, Yuhao Xue, Ying Wang, Ziyuan Shen, Tianci Li, Jingjing Ye, Bingzong Li, Chenlu He, Dashan Li, and Qinhua Liu
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Hepatosplenomegaly ,nomogram ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,RC254-282 ,Original Research ,validation ,business.industry ,CD5-positive ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Nomogram ,medicine.disease ,Lymphoma ,Brier score ,DLBCL ,Cohort ,Absolute neutrophil count ,prognosis ,CD5 ,medicine.symptom ,business ,Diffuse large B-cell lymphoma - Abstract
BackgroundCD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a rare subtype of DLBCL with invasive clinical features and poor prognosis. Current clinical variables based on prognostic systems for DLBCL are inadequate to accurately stratify the prognosis of CD5+ DLBCL.MethodsA total of 195 CD5+ DLBCL patients were retrospectively recruited from nine centers in Huaihai Lymphoma Working Group. MaxStat analysis was used to identify optimal cutoff points for continuous variables; univariable and multivariable Cox analyses were used for variable selection; Kaplan–Meier curve was used to analyze the value of variables on prognosis; and C-index, Brier score, and decision curve analysis were measured for predicting model performance.ResultsThe derivation and validation cohorts consisted of 131 and 64 patients. Of the whole cohort, median age at diagnosis was 61 years, of whom 100 (51.28%) were males and the 5‐year overall survival rate was 42.1%. MYC, BCL-2, and the coexpression of MYC/BCL-2 could distinguish the survival of CD5+ DLBCL. Multivariable analysis showed that age, IPI, red blood cell count, neutrophil count, MYC expression, and hepatosplenomegaly were independent predictors, and the prognostic nomogram was developed. The C‐index of the nomogram was 0.809 in the derivation and 0.770 in the validation cohort. Decision curve analysis proved that compared with IPI, the specific nomogram showed a better identification in CD5+ DLBCL.ConclusionThe proposed nomogram provided a valuable tool for prognosis prediction in patients with CD5+ DLBCL.
- Published
- 2021
37. Propensity Score Matching Analysis of the Influence of Waiting Time Satisfaction on Community Resident’s Satisfaction With Medical Institutions: An Extensive Survey of Outpatient Population in Shantou City of Southern China
- Author
-
Jiahong Tian, Shoupei Chen, Yuqiu Zhou, Weiying Guo, Xueqin Huang, and Guanhua Fan
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Public aspects of medicine ,RA1-1270 - Abstract
Objective: This study was designed to perform a nuanced analysis of the multifaceted association between community residents’ satisfaction and their perceived satisfaction concerning the visit duration at medical facilities, that could be harnessed to enhance and streamline the process of hierarchical diagnosis and treatment, thereby augmenting healthcare outcomes and patient experiences. Methods: Respondents who had utilized services from medical institutions were invited to fill out questionnaires by scanning QR codes. Additionally, surveys also distributed questionnaires through WeChat groups of community residents in densely populated areas of the community, as well as WeChat groups for patients who had previously visited local hospitals. To balance differences between groups, propensity score matching was applied to analyze the contrast between residents satisfied and dissatisfied with their medical visits. After eliminating the interference of confounding factors, a comparative analysis was conducted on the relationship between resident satisfaction and medical institution experience.After eliminating the interference of confounding factors, a comparative analysis was conducted to delve deeply into the relationship between residents’ satisfaction and their experiences at medical facilities. Results: The study incorporated a large dataset encompassing 2356 community residents. Upon successful propensity score matching, logistic regression analysis elucidated several determinants of overall resident satisfaction. Notably, the grade of the medical institution (χ 2 = 8.226, P
- Published
- 2024
- Full Text
- View/download PDF
38. Adverse drug reaction analysis of a case of mental disorder caused by radical treatment of Helicobacter pylori infection
- Author
-
Kourong Shi, Xiaojun Ni, Weiying Gu, and Qiuzhen Zhu
- Subjects
Pharmacology ,Radical treatment ,Helicobacter pylori infection ,medicine.medical_specialty ,business.industry ,Internal medicine ,Drug Discovery ,medicine ,Pharmaceutical Science ,medicine.disease ,business ,Gastroenterology ,Adverse drug reaction - Published
- 2020
39. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway
- Author
-
Yongqing Jia, Weiying Gu, Xiaoxiao Wang, Yanbei Sun, Tingxiu Jiang, and Jingyun Zou
- Subjects
Male ,0301 basic medicine ,Proliferative disease ,Transplantation, Heterologous ,Mice, Nude ,Apoptosis ,Protein Serine-Threonine Kinases ,Biology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Cell Adhesion ,medicine ,Animals ,Humans ,Hippo Signaling Pathway ,Phosphorylation ,RNA, Small Interfering ,Molecular Biology ,Multiple myeloma ,Adaptor Proteins, Signal Transducing ,Cell Proliferation ,Mir 181a 5p ,MALAT1 ,YAP-Signaling Proteins ,Cell Biology ,Adhesion ,medicine.disease ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,RNA, Long Noncoding ,Signal transduction ,Multiple Myeloma ,Research Paper ,Signal Transduction ,Transcription Factors ,Developmental Biology - Abstract
Multiple myeloma (MM) is a plasma cells malignant proliferative disease, especially in aged people. LncRNAs have been considered as important regulators in MM. This research was to study the effect of LncRNA MALAT1 on the proliferation and adhesion of myeloma cells and whether Long non-coding RNAs MALAT1(LncRNA MALAT1) plays its regulative role through Hippo-YAP signaling pathway by targeting miR-181a-5p. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was used to detect the LncRNA MALAT1/miR-181a-5p expression and improve the transfection efficiency. Western blot analysis was used to analyze the expression of proliferation and apoptosis related proteins and Hippo-Yes-associated protein (YAP) signaling pathway related proteins. Cell proliferative ability and cell apoptosis were respectively determined by Cell Counting Kit-8 (CCK-8) assay and flow cytometry analysis. ELISA assay was for the determination of adherence factors. Immunohistochemistry was to detect the expression of proliferation and adhesion related proteins. LncRNA MALAT1 targeting gene was determined by Dual-luciferase reporter assay. LncRNA MALAT1 was increased in MM cells and LncRNA MALAT1 interference could inhibit cell proliferation and promote cell apoptosis with the changes in the related proteins. Also, LncRNA MALAT1 interference could inhibit cell adhesion through Hippo-YAP signaling pathway. MiR-181a-5p was demonstrated to be a target of LncRNA MALAT1 and miR-181a-5p overexpression could also regulate the changes in cellular behavior in accordance with the LncRNA MALAT1 interference. In addition, LncRNA MALAT1 interference could decrease the expression of miR-181a-5p and inhibit the growth of tumor. In conclusion, this study showed that LncRNA MALAT1 interference inhibited the proliferation and adhesion of myeloma cells by the up-regulation of miR-181a-5p through activating the Hippo-YAP signaling pathway.
- Published
- 2019
40. The Value of Prognostic Nutritional Index (PNI) on Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: A Multicenter Retrospective Study of HHLWG Based on Propensity Score Matched Analysis
- Author
-
Weiying Gu, Wei Sang, Yuhao Xue, Yuye Shi, Ziyuan Shen, Dashan Li, Hao Zhang, Taigang Zhu, Chenlu He, Shanlin Nie, Zhenzhen Bian, Mingkang Yao, Yuqing Miao, Shuiping Huang, Ying Wang, and Fei Wang
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Proportional hazards model ,Immunology ,diffuse large B-cell lymphoma ,Retrospective cohort study ,propensity score matched ,medicine.disease ,Lymphoma ,prognostic nutrition index ,International Prognostic Index ,Internal medicine ,hemic and lymphatic diseases ,Propensity score matching ,Immunology and Allergy ,Medicine ,prognosis ,Stage (cooking) ,Journal of Inflammation Research ,business ,Diffuse large B-cell lymphoma ,Prognostic Nutritional Index (PNI) ,Original Research - Abstract
Ziyuan Shen,1,* Fei Wang,2,* Chenlu He,1,* Dashan Li,3 Shanlin Nie,3 Zhenzhen Bian,3 Mingkang Yao,4 Yuhao Xue,5 Ying Wang,6 Weiying Gu,2 Taigang Zhu,7 Yuye Shi,5 Hao Zhang,4 Shuiping Huang,1,8 Yuqing Miao,9 Wei Sang3 On behalf of the Huaihai Lymphoma Working Group1Department of Epidemiology and Biostatistics, Xuzhou Medical University, Xuzhou, Jiangsu, Peopleâs Republic of China; 2Department of Hematology, The First Peopleâs Hospital of Changzhou, Changzhou, Jiangsu, Peopleâs Republic of China; 3Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, Peopleâs Republic of China; 4Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong, Peopleâs Republic of China; 5Department of Hematology, The First Peopleâs Hospital of Huaian, Huaian, Jiangsu, Peopleâs Republic of China; 6Department of Personnel, Suqian First Hospital, Suqian, Jiangsu, Peopleâs Republic of China; 7Department of Hematology, The General Hospital of Wanbei Coal-Electric Group, Suzhou, Peopleâs Republic of China; 8Center for Medical Statistics and Data Analysis, Xuzhou Medical University, Xuzhou, Jiangsu, Peopleâs Republic of China; 9Department of Hematology, Yancheng First Peopleâs Hospital, Yancheng, Jiangsu, Peopleâs Republic of China*These authors contributed equally to this workCorrespondence: Wei SangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, Peopleâs Republic of ChinaTel +8613645207648Email xyfylbl515@xzhmu.edu.cnYuqing MiaoDepartment of Hematology, Yancheng First Peopleâs Hospital, Yancheng, Jiangsu, Peopleâs Republic of ChinaTel +8613851342032Email miaomiaomyq@163.comIntroduction: Immunonutritional status is associated with the survival of DLBCL. This multicenter retrospective study aimed to explore the prognostic value of Prognostic Nutrition Index (PNI) in DLBCL patients by using propensity score matched analysis (PSM).Methods: A total of 990 DLBCL cases were recruited from 5 centers of Huaihai Lymphoma Working Group (HHLWG). A 1:1 PSM analysis was performed using the nearest-neighbor method, with a caliper size of 0.02. Cox regression analysis was used to examine factors associated with survival.Results: The median age at diagnosis was 62 years and 52.5% were males, with the 3-y overall survival of 65.1%. According to the MaxStat analysis, 44 was the optimal cut-off point of PNI. After PSM analysis, a total of 282 patients in PNI < 44 group could be propensity matched to PNI ⥠44 patients, creating a group of 564 patients. Multivariable analysis revealed that PNI, age, central nervous system involvement and International Prognostic Index (IPI) were independent prognostic factors for DLBCL. KaplanâMeier analysis indicated that patients with low PNI in Ann Arbor Stage (III/VI), ECOG (< 2), IPI (LR+LIR), GCB, and BCL-2 negative groups had a poor prognosis.Discussion: PNI could accurately stratify the prognosis of DLBCL after PSM analysis.Keywords: diffuse large B-cell lymphoma, prognostic nutrition index, propensity score matched, prognosis
- Published
- 2021
41. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group
- Author
-
Ziyuan, Shen, Lingling, Hu, Mingkang, Yao, Chenlu, He, Qinhua, Liu, Fei, Wang, Weiying, Gu, Ying, Wang, Manyu, Dong, Taigang, Zhu, Ting, Yin, Fei, Li, Yingliang, Jin, Shuiping, Huang, Hao, Zhang, and Wei, Sang
- Subjects
Adult ,Aged, 80 and over ,Male ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Middle Aged ,Lymphoma, T-Cell ,Prognosis ,Hodgkin Disease ,Diagnosis, Differential ,Survival Rate ,DNA, Viral ,Humans ,Female ,Lymphoma, Large B-Cell, Diffuse ,Lymphoma, Follicular ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
Elevated Epstein-Barr virus (EBV) DNA load is common in lymphomas. However, it remains unclear whether the disparity in viral load and its prognostic value in lymphomas are correlated with Epstein-Barr encoding region (EBER) status. In this retrospective multicenter study, we collected the data of pretreatment whole blood EBV DNA (pre-EBV DNA) and EBER status and evaluated their disparity and prognostic values in lymphomas. A total of 454 lymphoma patients from December 2014 to August 2020 were retrospectively retrieved. Mann-Whitney U test, Kruskal-Wallis test and Bonferroni's adjustment were used to explore the disparity of EBV DNA and EBER status in lymphomas. Time-dependent receiver operating characteristic analysis and MaxStat analysis were used to determine optimal cutoff points of pre-EBV DNA load. Univariable and multivariable Cox proportional hazards models were established for the estimation of prognostic factors. The positive rate of EBV DNA in natural killer T-cell lymphoma (NKTL) patients was higher than that in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) patients, and the median positive pre-EBV copy number of NKTL was also higher than that of FL and DLBCL. EBV DNA could clearly distinguish the prognosis of DLBCL, NKTL, HL and peripheral T-cell lymphoma, and the integration of EBER status and EBV DNA could differentiate the prognosis of HL patients. Multivariable results revealed that pre-EBV DNA load had an effect on the prognosis of NKTL, FL and DLBCL. The status of pre-EBV DNA and EBER were disparate. Whole blood pre-EBV DNA predicted the prognosis of lymphomas, and the combination of EBV and EBER status could differentiate the prognosis of HL.
- Published
- 2021
42. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
- Author
-
Ying-Li Wu, Hua Yan, Zilu Zhang, Yanjie Ji, Huizhuang Shan, Yang Cao, Xiaoguang Xu, Hu Lei, Weiying Gu, Zhixiao Fang, Zhi-lei Bu, Jia Liu, Meng Liu, Yue Liu, Wanting Liu, Xingming Zhang, Hanzhang Xu, and Miao Yu
- Subjects
Cancer Research ,Cell cycle checkpoint ,Indoles ,medicine.drug_class ,Genes, myb ,Immunology ,Myeloma ,Apoptosis ,Tyrosine-kinase inhibitor ,Article ,Bortezomib ,Cellular and Molecular Neuroscience ,In vivo ,Target identification ,Cell Line, Tumor ,medicine ,Tumor Microenvironment ,Humans ,Cytotoxicity ,Protein Kinase Inhibitors ,Multiple myeloma ,Cell Proliferation ,QH573-671 ,Chemistry ,Cell Biology ,medicine.disease ,medicine.anatomical_structure ,Cancer research ,Quinolines ,Bone marrow ,Signal transduction ,Neoplasm Recurrence, Local ,Cytology ,Multiple Myeloma ,Signal Transduction - Abstract
Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor (TKI), has exhibited encouraging antitumor activity in several preclinical and clinical trials, but its effect on MM has not been studied yet. In this study, we found that anlotinib exhibits encouraging cytotoxicity in MM cells, overcomes the protective effect of the bone marrow microenvironment and suppresses tumor growth in the MM mouse xenograft model. We further examined the underlying molecular mechanism and found that anlotinib provokes cell cycle arrest, induces apoptosis and inhibits multiple signaling pathways. Importantly, we identify c-Myc as a novel direct target of anlotinib. The enhanced ubiquitin proteasomal degradation of c-Myc contributes to the cell apoptosis induced by anlotinib. In addition, anlotinib also displays strong cytotoxicity against bortezomib-resistant MM cells. Our study demonstrates the extraordinary anti-MM effect of anlotinib both in vitro and in vivo, which provides solid evidence and a promising rationale for future clinical application of anlotinib in the treatment of human MM.
- Published
- 2021
43. Up-regulation of circPVT1 in T cell acute lymphoblastic leukemia promoted cell proliferation via miR-30e/DLL4 induced activating NOTCH signaling
- Author
-
Weiying Gu and Yongqing Jia
- Subjects
0301 basic medicine ,T cell ,Notch signaling pathway ,Apoptosis ,Biology ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,medicine ,Humans ,Adaptor Proteins, Signal Transducing ,Cell Proliferation ,Oncogene ,Competing endogenous RNA ,Cell growth ,Calcium-Binding Proteins ,Cell Biology ,RNA, Circular ,Up-Regulation ,MicroRNAs ,030104 developmental biology ,medicine.anatomical_structure ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,RNA, Long Noncoding ,Signal Transduction - Abstract
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer with dismal prognosis. Recent studies disclosed that circPVT1 played an oncogene role in various cancers. But its role in T-ALL is still unclear. In this study, we found the expression levels of circPVT1 in bone marrows and cell lines of T-ALL were significantly up regulated and knock-down of circPVT1 in T-ALL cell lines could inhibit the cell proliferation and increase the cell apoptosis. Further analysis showed that circPVT1 could bind directly to miR-30e and contributed to the activate the Notch signaling by regulating miR-30e/DLL4 pathway. The levels of circPVT1 were obviously related to cumulative relapse rate and 5-year survival rate. In conclusion, our study reveals that circPVT1 participates in the progression of T-ALL through the miR-30e/DLL4 pathway and might represent a potential therapeutic target for T-ALL treatment.
- Published
- 2021
44. An Atypical PML-RARA Rearrangement Resulting from Submicroscopic Insertion of the RARA Gene at the PML Locus with Novel Breakpoints within PML Exon 7b and RARA Exon 3
- Author
-
Zhi-lin Wang, Rongrong Lin, Jiannong Cen, Yue Liu, Xiaobao Xie, Li Yao, Weiying Gu, Quan Gu, Suning Chen, Fei Wang, Weimin Dong, and Yang Cao
- Subjects
Acute promyelocytic leukemia ,medicine.diagnostic_test ,Breakpoint ,breakpoint cluster region ,Chromosomal translocation ,Hematology ,General Medicine ,Biology ,medicine.disease ,Minimal residual disease ,Molecular biology ,03 medical and health sciences ,Exon ,0302 clinical medicine ,MRNA Sequencing ,030220 oncology & carcinogenesis ,medicine ,030215 immunology ,Fluorescence in situ hybridization - Abstract
The diagnostic hallmark of acute promyelocytic leukemia (APL) is the reciprocal translocation t(15;17), resulting in the characteristic PML-RARA fusion; however, patients occasionally have masked PML-RARArearrangements. We report an APL case with no evidence of t(15;17) or PML-RARA rearrangement by karyotype or commercial reverse transcription polymerase chain reaction analyses. Fluorescence in situ hybridization detected a small RARA insertion signal within PML. mRNA sequencing identified a novel PML-RARA transcript generated from the juxtaposition of PMLIIa (exons 1–4, 6, and 7ab) and RARA exons (3–9), with novel breakpoints in PML exon 7b and RARA exon 3. The patient achieved molecular remission after the second consolidation chemotherapy and remains in complete remission 22 months after initial presentation. This is the first report of an APL case presenting with submicroscopic ins(15;17) and simultaneous novel breakpoints in both PML and RARA. This case highlights the importance of sequence analysis to confirm APL diagnosis and for subsequent monitoring of minimal residual disease.
- Published
- 2019
45. Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment‑related cardiotoxicity after anthracycline chemotherapy in patients with diffuse large B‑cell lymphoma
- Author
-
Bai He, Yan Lin, Jianfeng Wang, Yanting Guo, Chun Qiu, Peng Xu, Weiying Gu, Limei Shang, Xiaobao Xie, Min Xu, Weimin Dong, Yuetao Wang, Feng Li, Fei Wang, and Yanhua Yue
- Subjects
summed rest score ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Anthracycline ,medicine.medical_treatment ,diffuse large B-cell lymphoma ,Infarction ,03 medical and health sciences ,Myocardial perfusion imaging ,0302 clinical medicine ,stomatognathic system ,Internal medicine ,Medicine ,cardiovascular diseases ,Chemotherapy ,Cardiotoxicity ,Ejection fraction ,medicine.diagnostic_test ,business.industry ,Articles ,medicine.disease ,treatment-related cardiotoxicity ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Heart failure ,cardiovascular system ,Cardiology ,business ,gated myocardial perfusion imaging ,Diffuse large B-cell lymphoma - Abstract
Anthracycline chemotherapy is commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL). Treatment-related cardiotoxicity (TRC) is defined as when the patient is identified to have one of the following clinical manifestations: Symptomatic heart failure, cardiac death, arrhythmia, infarction, a decrease in left ventricular ejection fraction (LVEF) of >15% from baseline or a decrease in LVEF of >10 to 1 for predicting TRC after anthracycline chemotherapy (P
- Published
- 2020
46. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review
- Author
-
Weimin Dong, Yanting Guo, Yan Lin, Yang Cao, Fei Wang, Wei Wei, Yanhua Yue, Weiying Gu, and Yue Liu
- Subjects
Myelofibrosis ,030204 cardiovascular system & hematology ,Gene mutation ,03 medical and health sciences ,Myelogenous ,0302 clinical medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,medicine ,Humans ,Myeloproliferative Disorders ,ABL ,business.industry ,breakpoint cluster region ,Articles ,General Medicine ,Janus Kinase 2 ,Middle Aged ,medicine.disease ,Dasatinib ,Leukemia ,Primary Myelofibrosis ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Female ,business ,Chronic myelogenous leukemia ,medicine.drug - Abstract
Patient: Female, 50-year-old Final Diagnosis: Chronic myeloid leukaemia Symptoms: Dizziness • weakness Medication: — Clinical Procedure: — Specialty: Hematology Objective: Unusual clinical course Background: Although the V617F mutation in the Janus kinase 2 (JAK2) gene and the breakpoint cluster region-abl1 (BCRABL1) oncogene fusion have been considered mutually exclusive in most myeloproliferative neoplasms (MPNs), many recent studies have described patients with both. This report describes a patient with chronic myelogenous leukemia (CML) and the unusual JAK2 R795S mutation and reviews 23 additional patients with JAK2 gene mutations coexisting with myelofibrosis (MF) and CML. Case Report: A 50-year-old woman with MF experienced rapid disease progression 3 weeks later, accompanied by severe abdominal pain and a white blood cell count of 257.45×109/l. Karyotype analysis indicated that she was 46, XY, Philadelphia (Ph) (+) and BCR-ABL1 positive. Bone marrow aspiration after 1 cycle of chemotherapy and treatment with dasatinib showed that her marrow was hypercellular, with an increased number of megakaryocytes and 48.5% myeloblasts expressing the myeloid antigens CD33, CD13, CD34, CD117, and CD71. Next-generation sequencing identified a rare JAK2 R795S mutation. She was diagnosed with CML in blast phase, and was successfully treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Conclusions: JAK2 gene mutations, including the rare JAK2 R795S mutation, can coexist with BCR-ABL1 in patients with MPNs. The clinical course of MPN in patients with both BCR-ABL1 and JAK2 mutations may be different from that in patients with classical MPNs.
- Published
- 2020
47. Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment-related cardiotoxicity after anthracycline chemotherapy in diffuse large B-cell lymphoma patients
- Author
-
Feng Li, Chun Qiu, Yanhua Yue, Min Xu, Peng Xu, Fei Wang, Yanting Guo, Jianfeng Wang, Yuetao Wang, Yan Lin, Weimin Dong, Xiaobao Xie, Limei Shang, Bai He, and Weiying Gu
- Subjects
Cardiotoxicity ,medicine.medical_specialty ,Chemotherapy ,Anthracycline ,medicine.diagnostic_test ,business.industry ,Summed rest score ,medicine.medical_treatment ,medicine.disease ,Myocardial perfusion imaging ,Internal medicine ,Cardiology ,Medicine ,business ,Diffuse large B-cell lymphoma - Abstract
Background: Anthracycline chemotherapy is commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) patients. Treatment-related cardiotoxicity (TRC) may be observed during treatment and may induce severe cardiac failure or cardiac arrhythmia as the main cause of death, even several years after chemotherapy implementation. Herein, we performed a study to investigate the prognostic value of gated myocardial perfusion imaging (G-MPI) summed rest score (SRS) for the early detection of TRC caused by anthracycline chemotherapy in DLBCL patients.Methods: A total of 36 DLBCL patients were enrolled, and a series of parameters from the same individual patient were compared between baseline and after the end of the 6th R-CHOP chemotherapeutic regimen. According to whether TRC occurred during the observation period, the patients were divided into two groups, and parameters related to cardiac function were compared.Results: SRS in G-MPI and QTc interval in electrocardiogram were significantly different before and after chemotherapy (P = 0.012 and P = 0.015, respectively).By comparing parameters related to cardiac function between the TRC group (n = 22) and the no-TRC group (n = 14), only SRS was significantly different (P = 0.012). Multivariate logistic regression analysis showed that the SRS level was the only independent predicator for TRC (P = 0.018, HR = 6.053, 95% CI: 1.364-26.869). Receiver operating characteristic curve analysis identified an optimal SRS cutoff of >1for predicting TRC after anthracycline chemotherapy (P< 0.001).Conclusion: The G-MPI SRS level was an early indicator for TRC surveillance in DLBCL patients after anthracycline chemotherapy, thus contributing to early treatment and a subsequent decrease in mortality caused by such cardiovascular complications.
- Published
- 2020
48. AML-063 Genomic Profiling of Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Author
-
Xiaoxuan Wang, Yanting Guo, Huijuan Chen, Limei Shang, Xiangjing Hu, Yan Liu, Chao Song, Weiying Gu, and Wei Wei
- Subjects
Oncology ,medicine.medical_specialty ,Cancer Research ,Genomic profiling ,Somatic cell ,business.industry ,Myeloid leukemia ,Hematology ,Gene mutation ,Peripheral blood ,Pathogenesis ,Bone marrow aspirate ,hemic and lymphatic diseases ,Internal medicine ,medicine ,business ,Gene - Abstract
Objective: In this study, we aimed to investigate the genomic differences between Chinese patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), as well as the difference between Asian and Western patients. Methods: We systematically analyzed somatic alterations of fresh bone marrow aspirate or peripheral blood specimens from 58 patients with AML and 26 patients with MDS with a hybridization capture-based next-generation sequencing (NGS) panel, including 196 genes known to be somatically altered in human hematological malignancies. Results: At least one non-synonymous gene mutation was detected in 54 AML patients (93.1%) and 23 MDS patients (95.83%). Compared with AML patients aged Conclusions: In this study, we elucidated the landscape of gene mutations in Chinese AML/MDS, and we further identified significant genomic differences between Asian and Western patients, which should improve our understanding of pathogenesis and/or lead to a better selection of targeted therapies.
- Published
- 2021
49. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
- Author
-
Hongqin Xu, Hongyan Li, Hailong You, Peng Zhang, Nan Li, Nan Jiang, Yang Cao, Ling Qin, Guixiang Qin, Hongbo Qu, Heyuan Wang, Bo Zou, Xia He, Dan Li, Huazhong Zhao, Gang Huang, Yang Li, Hefeng Zhang, Liping Zhu, Hongmei Qiao, Hongjun Li, Shurong Liu, Lina Gu, Guidong Yin, Ye Hu, Songbai Xu, Weiying Guo, Nanya Wang, Chaoying Liu, Pujun Gao, Jie Cao, Yang Zheng, Kaiyu Zhang, Yang Wang, Hui Chen, Jian Zhang, Dongmei Mu, and Junqi Niu
- Subjects
COVID-19 ,SARS-CoV-2 ,Omicron ,vaccine ,pneumonia ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
ABSTRACTIt is critical to determine the real-world performance of vaccines against coronavirus disease 2019 (COVID-19) so that appropriate treatments and policies can be implemented. There was a rapid wave of infections by the Omicron variant in Jilin Province (China) during spring 2022. We examined the effectiveness of inactivated vaccines against Omicron using real-world data from this epidemic. This retrospective case-case study of vaccine effectiveness (VE) examined infected patients who were quarantined and treated from April 16 to June 8, 2022 and responded to an electronic questionnaire. Data were analyzed by univariable and multivariable analyses. A total of 2968 cases with SARS-CoV-2 infections (asymptomatic: 1061, mild disease: 1763, pneumonia: 126, severe disease: 18) were enrolled in the study. Multivariable regression indicated that the risk for pneumonia or severe disease was greater in those who were older or had underlying diseases, but was less in those who received COVID-19 vaccines. Relative to no vaccination, VE against the composite of pneumonia and severe disease was significant for those who received 2 doses (60.1%, 95%CI: 40.0%, 73.5%) or 3 doses (68.1%, 95%CI: 44.6%, 81.7%), and VE was similar in the subgroups of males and females. However, VE against the composite of all three classes of symptomatic diseases was not significant overall, nor after stratification by sex. There was no statistical difference in the VE of vaccines from different manufacturers. The inactivated COVID-19 vaccines protected patients against pneumonia and severe disease from Omicron infection, and booster vaccination enhanced this effect.
- Published
- 2023
- Full Text
- View/download PDF
50. The clinical characteristics and prognostic significance of AID, miR-181b, and miR-155 expression in adult patients withde novoB-cell acute lymphoblastic leukemia
- Author
-
Xiao-ying Hua, Jiannong Cen, Shaoyan Hu, Weimin Dong, Xiaobao Xie, Wei Wu, Qi Wang, Weiying Gu, Yang Cao, Guangquan Zhou, Yun Ling, and Yan Lin
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Lymphoblastic Leukemia ,Kaplan-Meier Estimate ,miR-155 ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cytidine Deaminase ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Internal medicine ,Odds Ratio ,Activation-induced (cytidine) deaminase ,Humans ,Medicine ,Gene ,biology ,Adult patients ,business.industry ,Hematology ,Cytidine deaminase ,B-cell acute lymphoblastic leukemia ,Middle Aged ,Prognosis ,MicroRNAs ,030104 developmental biology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Immunology ,biology.protein ,Female ,business ,Risk classification - Abstract
This study aimed to investigate clinical characteristics and prognostic significance of activation-induced cytidine deaminase (AID) gene, miR-181b and miR-155 expression in de novo adult B-cell acute lymphoblastic leukemia (B-ALL) patients. Results showed that AID and miR-155 expression were higher in B-ALL patients than healthy controls, while miR-181b expression was lower in B-ALL patients. In addition, Ph+ B-ALLs had higher AID expression than Ph- B-ALLs, and its high expression was associated with BCR-ABL. Moreover, B-ALL patients with AIDhigh or miR-181blow expression had a shorter overall survival (OS). AIDhigh with miR-181blow, AIDhigh with miR-155low, miR-181blow, miR-155low, AIDhigh with miR-181blow and miR-155low expression were associated with shorter OS. Combination of the three molecules are more accurate predictors for unfavorable OS compared with univariate group. Therefore, AID, miR-181b and miR-155 provide clinical prognosis of adult de novo B-ALL patients and may refine their molecular risk classification.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.